Behavioral effects of acetyl-l-carnitine in the male rat

Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites

Mitochondria decay with age due to the oxidation of lipids, proteins, RNA, and DNA. Some of this decay can be reversed in aged animals by feeding them the mitochondrial metabolites acetylcarnitine and lipoic acid. In this review, we summarize our recent studies on the effects of these mitochondrial metabolites and mitochondrial antioxidants (alpha-phenyl-N-t-butyl nitrone and N-t-butyl hydroxylamine) on the age-associated mitochondrial decay of the brain of old rats, neuronal cells, and human diploid fibroblast cells. In feeding studies in old rats, these mitochondrial metabolites and antioxidants improve the age-associated decline of ambulatory activity and memory, partially restore mitochondrial structure and function, inhibit the age-associated increase of oxidative damage to lipids, proteins, and nucleic acids, elevate the levels of antioxidants, and restore the activity and substrate binding affinity of a key mitochondrial enzyme, carnitine acetyltransferase. These mitochondrial metabolites and antioxidants protect neuronal cells from neurotoxin- and oxidant-induced toxicity and oxidative damage; delay the normal senescence of human diploid fibroblast cells, and inhibit oxidant-induced acceleration of senescence. These results suggest a plausible mechanism: with age, increased oxidative damage to proteins and lipid membranes, particularly in mitochondria, causes a deformation of structure of enzymes, with a consequent decrease of enzyme activity as well as substrate binding affinity for their substrates; an increased level of substrate restores the velocity of the reaction and restores mitochondrial function, thus delaying mitochondrial decay and aging. This loss of activity due to coenzyme or substrate binding appears to be true for a number of other enzymes as well, including mitochondrial complex III and IV.

Enantiomeric purity determination of acetyl-L-carnitine by reversed-phase high-performance liquid chromatography using chiral derivatization

An indirect HPLC enantioseparation method for the determination of acetyl-D-carnitine (D-AC) in acetyl-L-carnitine (L-AC) was developed. L-AC was derivatized with a chiral amino compound which has a chromophore for UV detection. Six chiral amino compounds were examined as chiral derivatization reagents. Among them, enantiomers of acetylcarnitine derivatized with L-alanine-beta-naphthylamide (L-Ala-beta-NA) were successfully separated on an ODS column within 10 min with Rs = 1.94 and alpha = 1.10. Quantitation was achieved through UV detection at 254 nm. The derivatization reaction of L-AC with L-Ala-beta-NA was completed in less than 10 min at room temperature (ca. 20 degrees C). Validation data such as linearity, detection limit, and precision are also presented. The detection limit of D-AC in L-AC in this method was below 0.05% (visual evaluation). This method was found to be applicable as a practical quality control method for the enantiomeric purity determination of L-AC.

Effects of RGH 2202 on cognitive and motor behavior of the rat

The behavioral activity of the thyrotropin-releasing hormone (TRH) analogue, L-6-ketopiperidine-2-carbonyl-leucyl-L-prolinamide (RGH 2202), has been studied in animal models of central neurotransmission disruption. In 24-month-old rats, repeated administration of the peptide (5 or 10 mg/kg/day, injected IP for 20 days) was followed by a facilitated acquisition of active avoidance behavior in the shuttle-box test and retention of passive avoidance reaction in a step-through passive avoidance task. Also, ambulation in an open field was increased and motor performance and co-ordination in the rotorod test was facilitated by the treatment. Scopolamine-induced amnesia was reverted by RGH 2202 in adult rats tested both in active and passive avoidance tasks. Cognitive deficits induced in rats by prenatal manipulation with methylazoxymethanol (MAM) were reduced in adulthood by repeated administration with RGH 2202. These results indicate that the TRH-analogue, RGH 2202 may improve cognitive and motor disturbances in aging or induced by central neurotransmission disruption. It is possible that the peptide is functioning, at least in part, by intervening with the central cholinergic neurotransmission.

Minaprine facilitates acquisition and retrieval of an active avoidance response in the rat

The nootropic activity of 3-(2-morpholino-ethylamino)-4-methyl-6-phenyl-pyridazine dihydrochloride (minaprine) has been investigated in intact male, adult Long Evans rats by means of an active avoidance paradigm. In the light-dark box apparatus, the rat had to learn the active avoidance response of going out of the normally preferred dark chamber to avoid electric foot-shocks. These were administered during one trial per day for 3 consecutive days (acquisition period). After a 72-h interval, rats underwent, for 3 consecutive days, one trial per day in which punishments were omitted (retrieval period). In the first experiment, rats were injected IP with minaprine (5, 10, and 25 mg/kg b.w.) 30 min before each trial of both periods. Rats injected with the two lower dosages showed better responding during the retrieval period than controls (saline). On the contrary, the highest dosage impaired active avoidance during both periods. In Experiment 2, minaprine (10 mg/kg b.w.) was administered either only during the acquisition or only during the retrieval period. In both instances, active avoidance was equally enhanced, if compared to controls (saline), only during the retrieval period. The results are discussed on the basis of the known facilitating activity on cholinergic systems of this compound. It is concluded that minaprine acts positively both on acquisition and retrieval of mnemonic traces.

Effect of carnitine feeding on the levels of heart and skeletal muscle carnitine of elderly mice

Aging has been associated with an increase in muscle dysfunction and weakness. We found a decrease in muscle carnitine with age [Biochem. Biophys. Res. Commun., 161 (1989) 1135-1143]. Prolonged oral administration to both young (2-month-old) and adult (7-month-old) mice with L-carnitine increased its content in blood by 50%. The levels of carnitine in skeletal and heart muscle of old treated animals became higher than in untreated mice of the same age. However, this extensive restoration did not reach the maximum values present in skeletal muscle of young mice. Our findings indicate that an alteration of the carnitine carrier in the sarcolemma could be responsible for the decrease with age of carnitine in skeletal but not in heart muscle.

Effects of acetyl-L-carnitine on the survival of adult rat sensory neurons in primary cultures

Acetyl-L-carnitine produces a significant increase in the survival time-course of adult rat sensory neurons maintained in primary cultures up to 40 days. The analysis of our data suggests that 200 microM acetyl-L-carnitine added to the medium, slows down neuronal decay especially in the first 10 days in vitro, sparing a fraction of cells which would otherwise be lost. Patch-clamp recordings from these neurons show that superfusion with acetyl-L-carnitine (100-1000 microM) does not induce any membrane current. In addition an agonist muscarinic effect particularly concerning high-voltage activated calcium channel modulation appears to be ruled out. In conclusion our data favour the role of acetyl-L-carnitine in the trophism of sensory neurons in adult rats. In agreement with other in vivo experiments our data reinforce the hypothesis that this substance might be involved in reducing neuronal loss observed in nervous system aging.

Acetylcarnitine reduces the immobility of rats in a despair test (constrained swim)

Male rats forced to swim in a cylinder adopted an immobile posture. Immobility was reduced by acetylcarnitine (5, 10, and 20 mg/kg) and by antidepressant drugs, such as desipramine and iproniazid, injected 24, 5, and, again, 1 h prior to behavioral testing. Acetylcarnitine also potentiated the anti-immobility effect of antidepressant drugs in the despair test. Chronic (10 days) treatment with acetylcarnitine mimicked the effect found after acute administration. It is possible that the action of the acetylcarnitine on the despair test is indicative of an antidepressant activity of this drug that is dependent on a change in the sensitivity of monoamine receptors in the brain.

Acetyl-1-carnitine. 1: Effects on mortality, pathology and sensory-motor performance in aging rats

Three different test sites assessed the effects of acetyl-1-carnitine (AC) on age-related changes in general health, sensory-motor skills, learning, and memory. Two groups of rats began the experiments at 16 months of age. One group (OLD-AC) was given AC, 75 mg/kg/day, beginning at 16 months. The other group (OLD-CON) was treated identically except it was not given the drug. Beginning at 22 months of age, these rats and a group of young (3-4 months old) rats (YG-CON) were given a series of sensory-motor tasks. AC decreased mortality, and had no reliable effect on body weight, fluid intake, or the general health of the rats. These data indicate that a chronic dose of AC does not interfere with food and water intake, and may increase longevity. An age-related decline of performance occurred in most of the sensory-motor tasks; locomotor activity was reduced in a novel environment and in a runwheel, and the ability to prevent falling was reduced in tests on a taut wire, rotorod, inclined screen, and several types of elevated bridges. An age-related decline of performance did not occur in grooming, or in the latency to initiate several different behaviors. AC had no effect on performance in any sensory-motor task. These data indicate that the improvements produced by AC in some tests of spatial memory may be due to the effects of AC on cognitive abilities rather than on sensory-motor skills.

Differential effect of acetyl-l-carnitine on open field behavior in young and old rats

Acetyl-l-carnitine (ALCAR) exerts antiaging effects with study we evaluated the effect of a chronic treatment with ALCAR (6 weeks, 50 mg/kg/day) on the open field behavior of 5-month-old and 26-month-old male Wistar rats. Old rats defecated more, made fewer crossings, and spent more time in the corner squares. However, it is difficult to interpret these findings in terms of an increase in emotional reactivity with age because locomotor performance generally has been found to be impaired in old rats. Consequently, treatment effects were analysed within age groups. ALCAR had no effect in young rats, but the old ALCAR-treated rats ambulated less and spent more time in the corner squares than the old control rats. We have interpreted this in terms of an enhanced emotional reactivity of old ALCAR-treated rats.

Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia

A randomized, double-blind, placebo-controlled, parallel-group clinical trial was carried out to compare 24-week periods of treatment with 1 g acetyl-l-carnitine twice daily and placebo in the treatment of patients with dementia of the Alzheimer type. A total of 36 patients entered the trial, of whom 20 patients (7 active, 13 placebo) completed the full 24 weeks. Whilst several of the efficacy indices showed little change in either group during the trial, there was an apparent trend for more improvement in the acetyl-l-carnitine group in relation to the Names Learning Test and a computerized Digit Recall Test, both related to aspects of short-term memory. Similarly, there was a trend for reaction time in the computerized classification test to show less deterioration in the active treatment group. Changes within groups, and changes between groups, failed to reach statistical significance, at least partially because of the small number of patients available for analysis. Two indices of overall therapeutic benefit showed a trend for less deterioration in the active-treatment group than in the placebo group. Nausea and/or vomiting occurred in 5 patients in the acetyl-l-carnitine group. Laboratory tests revealed no signs of drug toxicity. The results suggest that acetyl-l-carnitine may have a beneficial effect on some clinical features of Alzheimer-type dementia, particularly those related to short-term memory.

Carnitine acetyltransferase activity is not changed with age in rat brain and human platelets

Carnitine acetyltransferase activity was studied in different brain regions of the rat and in human platelets. The values of Km for carnitine and for acetyl-CoenzymeA (acetyl-CoA) were similar in cortex, hippocampus and striatum of the rat and in human platelets, suggesting that carnitine acetyltransferase might be a useful peripheral marker of its central activity. The activity of this enzyme was similar in the cortex and hippocampus of young and old rats. Furthermore, the determination of carnitine acetyltransferase activity in platelets from healthy volunteers showed no significant difference with age.

Effects of acetyl-L-carnitine on the brain lipofuscin content and emotional behavior in aged rats

The effects of long-term dosing with acetyl-L-carnitine (ALC) were examined in aged rats, and they were compared with those in young rats. ALC significantly reduced the lipofuscin deposition in the brain of aged rats. Emotional parameters such as locomotor activity and rearing behavior are lower in aged rats than in young rats, and these behaviors decreased in both age groups during the experiments. ALC diminished the decrease of these emotional behaviors, especially in rearing behavior in the aged rats. Furthermore, ALC had no effect on body weight gain. These results might reflect one of the main beneficial pharmacological mechanisms of ALC in clinical use.